Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit for more information.

Page 3 of 4

  1. To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically vent...

    Authors: Pär Ingemar Johansson, Morten Bestle, Peter Søe-Jensen, Klaus Tjelle Kristiansen, Jakob Stensballe, Niels Erikstrup Clausen and Anders Perner
    Citation: Trials 2020 21:746
  2. This study aims to determine the protection provided by Shenfu injection (a traditional Chinese medicine) against development of organ dysfunction in critically ill patients with coronavirus disease 2019 (COVI...

    Authors: Zong-Yu Wang, Shou-Zhi Fu, Liang Xu, Shu-Sheng Li, Ke-Jian Qian, Xian-Di He, Guo-Chao Zhu, Liang-Hai Li, Jun Zhang, Wen-Fang Li, Bing-Yu Qin, Chen-Liang Zhou and Peng-Lin Ma
    Citation: Trials 2020 21:738
  3. Primary objective: To estimate the effect of corticosteroids compared with usual care or placebo on mortality up to 28 days after randomization. Secondary objectives: To examine whether the effect of corticost...

    Authors: Jonathan A. C. Sterne, Janet Diaz, Jesús Villar, Srinivas Murthy, Arthur S. Slutsky, Anders Perner, Peter Jüni, Derek C. Angus, Djillali Annane, Luciano Cesar Pontes Azevedo, Bin Du, Pierre-Francois Dequin, Anthony C. Gordon, Cameron Green, Julian P. T. Higgins, Peter Horby…
    Citation: Trials 2020 21:734
  4. To assess the hypothesis that an adjunctive therapy with methylprednisolone and unfractionated heparin (UFH) or with methylprednisolone and low molecular weight heparin (LMWH) are more effective in reducing an...

    Authors: Stefano Busani, Martina Tosi, Pasquale Mighali, Paola Vandelli, Roberto D’Amico, Marco Marietta, Francesco Forfori, Abele Donati, Gilda Cinnella, Amato De Monte, Daniela Pasero, Giacomo Bellani, Carlo Tascini, Giuseppe Foti, Marco Ranieri and Massimo Girardis
    Citation: Trials 2020 21:724
  5. The primary aim of the present study is to examine the efficacy of an online intervention for poor sleep in the context of an ongoing stressful major life event, by assessing if this intervention can reduce in...

    Authors: Greg J. Elder, Pamela Alfonso-Miller, William C. M. Atkinson, Nayantara Santhi and Jason G. Ellis
    Citation: Trials 2020 21:704

    The Update to this article has been published in Trials 2021 22:913

  6. To investigate the potential efficacy of Nigella sativa (NS) oil supplementation on the outcomes of patients with mild Coronavirus Disease 2019 (COVID-19).

    Authors: Abdulrahman E. Koshak, Emad A. Koshak, Abdullah F. Mobeireek, Mazen A. Badawi, Siraj O. Wali, Husam M. Malibary, Ali F. Atwah, Meshari M. Alhamdan, Reem A. Almalki and Tariq A. Madani
    Citation: Trials 2020 21:703
  7. To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg or...

    Authors: Javed Akram, Shehnoor Azhar, Muhammad Shahzad, Waqas Latif and Khalid Saeed Khan
    Citation: Trials 2020 21:702

    The Correction to this article has been published in Trials 2022 23:150

    The Correction to this article has been published in Trials 2020 21:733

  8. • Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19.

    Authors: Miguel Rodríguez-Rubio, Juan Carlos Figueira, Darío Acuña-Castroviejo, Alberto M. Borobia, Germaine Escames and Pedro de la Oliva
    Citation: Trials 2020 21:699
  9. Stage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage.

    Authors: Tom Wilkinson, Rupert Dixon, Clive Page, Miles Carroll, Gareth Griffiths, Ling-Pei Ho, Anthony De Soyza, Timothy Felton, Keir E. Lewis, Karen Phekoo, James D. Chalmers, Anthony Gordon, Lorcan McGarvey, Jillian Doherty, Robert C. Read, Manu Shankar-Hari…
    Citation: Trials 2020 21:691
  10. To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: de...

    Authors: Ing Ni Lu, Spoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, Edward Banham-Hall, Sonakshi Kadyan, Simon Bond, Sam Norton, Andrew Cope, James Galloway, Frances Hall, David Jayne, Ian B. Wilkinson and Joseph Cheriyan
    Citation: Trials 2020 21:690
  11. Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion a...

    Authors: Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, Claudia Lilli, Chiara Zingaretti, Caterina Donati, Carla Masini, Manuela Monti, Patrizia Serra, Roberto Vespignani, Veruska Grossi, Annibale Biggeri, Emanuela Scarpi, Francesca Galardi, Lucia Bertoni, Americo Colamartini…
    Citation: Trials 2020 21:689
  12. The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome c...

    Authors: Berta Grau-Pujol, Daniel Camprubí, Helena Marti-Soler, Marc Fernández-Pardos, Caterina Guinovart and Jose Muñoz
    Citation: Trials 2020 21:688
  13. The trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or susp...

    Authors: Gavin D. Perkins, Keith Couper, Bronwen Connolly, J. Kenneth Baillie, Judy M. Bradley, Paul Dark, Anthony De Soyza, Ellen Gorman, Alasdair Gray, Louisa Hamilton, Nicholas Hart, Chen Ji, Ranjit Lall, Nicola McGowan, Scott Regan, Anita K. Simonds…
    Citation: Trials 2020 21:687
  14. To assess the efficacy of local intranasal treatment with budesonide (nasal irrigation), in addition to olfactory rehabilitation, in the management of loss of smell in COVID-19 patients without signs of severi...

    Authors: Mary Daval, Alain Corré, Clement Palpacuer, Juliette Housset, Guillaume Poillon, Michael Eliezer, Benjamin Verillaud, Dorsaf Slama, Denis Ayache, Philippe Herman, Clement Jourdaine, Camille Hervé, Wissame El Bakkouri, Dominique Salmon and Charlotte Hautefort
    Citation: Trials 2020 21:666
  15. Objective 1: To determine if it is feasible to conduct an RCT of online Sudarshan Kriya Yoga (SKY) for frontline hospital and long-term care home staff under the constraints imposed by the COVID-19 pandemic and n...

    Authors: Ka Sing Paris Lai, Christine Watt, Emily Ionson, Imants Baruss, Cheryl Forchuk, Javeed Sukhera, Amer M. Burhan and Akshya Vasudev
    Citation: Trials 2020 21:648
  16. Primary Objective: To determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily reduces microbiologically confirmed COVID-19 among front line health care workers at...

    Authors: Julie K. Wright, Darrell H. S. Tan, Sharon L. Walmsley, Jennifer Hulme, Erin O’Connor, Carolyn Snider, Ivy Cheng, Adrienne K. Chan, Bjug Borgundvaag, Shelley McLeod, Michael H. Gollob, Rosemarie J. Clarke, Linda Dresser, Fatima Haji, Tony Mazzulli, Samira Mubareka…
    Citation: Trials 2020 21:647
  17. To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-...

    Authors: Justin T. Denholm, Joshua Davis, David Paterson, Jason Roberts, Susan Morpeth, Thomas Snelling, Dominica Zentner, Megan Rees, Matthew O’Sullivan, David Price, Asha Bowen and Steven Y. C. Tong
    Citation: Trials 2020 21:646
  18. Primary Objective

    Authors: Keisha Smith, Amy Pace, Stephan Ortiz, Shamsah Kazani and Scott Rottinghaus
    Citation: Trials 2020 21:639
  19. The aim of this trial is to identify the effect of ambulatory treatment in early COVID-19 disease with hydroxychloroquine on the rate of hospitalization or death in older patients above the age of 64.

    Authors: Siri Göpel, Wolfgang Bethge, Peter Martus, Florian Kreth, Thomas Iftner, Stefanie Joos, Stefanie Döbele, Benjamin Mordmüller, Peter Kremsner, Thomas Ettrich, Thomas Seufferlein, Michael Bitzer and Nisar Malek
    Citation: Trials 2020 21:635
  20. The aim of this study is to explore the effectiveness and safety of oral corticosteroids (prednisone) in the treatment of early stage SARS-Cov-2 pneumonia in patients who do not yet meet hospital admission cri...

    Authors: Miriam Saiz-Rodríguez, Teresa Peña, Lourdes Lázaro, Ángel González, Andrés Martínez, José A. Cordero, Juan T. Vicente, Fernando Richard, María Jesús Coma, Martín de Frutos, Jorge Labrador and Ana Pueyo
    Citation: Trials 2020 21:632
  21. To determine if a specific immunomodulatory intervention reduces progression of COVID-19-related disease to organ failure or death, compared to standard of care (SoC).

    Authors: Spoorthy Kulkarni, Marie Fisk, Michalis Kostapanos, Edward Banham-Hall, Simon Bond, Elena Hernan-Sancho, Sam Norton, Joseph Cheriyan, Andrew Cope, James Galloway, Frances Hall, David Jayne and Ian B. Wilkinson
    Citation: Trials 2020 21:626
  22. This study will evaluate the main hypothesis that supplementation with vitamins A, B, C, D, and E significantly improves the severity and mortality rate in ICU patients with COVID-19.

    Authors: Mohammad Taghi Beigmohammadi, Sama Bitarafan, Azin Hoseindokht, Alireza Abdollahi, Laya Amoozadeh, Maedeh Mahmoodi Ali Abadi and Morteza Foroumandi
    Citation: Trials 2020 21:614
  23. As there is no treatment for COVID-19 with a proven mortality benefit at this moment in the pandemic, supportive management including mechanical ventilation is the core management in an intensive care unit (IC...

    Authors: Atsushi Kawaguchi, Gabrielle Bernier, Jacques Lacroix, Saly El Salti, Matthew P. Cheng, Todd C. Lee, Kosar Khwaja and Philippe Jouvet
    Citation: Trials 2020 21:610
  24. To evaluate the therapeutic effects of ultra-short-wave diathermy (SWD) on COVID-19 pneumonia. The hypothesis is that SWD may minimise pneumonic inflammation and shorten the duration of the time to positive-to...

    Authors: Mohammad Nasb, Zulfiqar Ali Sayed Shah, Liangjiang Huang, Qian Li and Hong Chen
    Citation: Trials 2020 21:609
  25. The primary objectives of the study are:

    Authors: Raquel González, Laura García-Otero, Clara Pons-Duran, Elena Marbán-Castro, Anna Goncé, Elisa Llurba, Maria del Mar Gil, Miguel Ángel Rodríguez-Zambrano, Haily Chen, Máximo Ramírez, Azucena Bardají and Clara Menendez
    Citation: Trials 2020 21:607
  26. To determine whether chemoprophylaxis with hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 (COVID-19) in frontline healthcare workers.

    Authors: Carmel M. McEniery, Marie Fisk, Karen Miles, Fotini Kaloyirou, Annette Hubsch, Jane Smith, Ian B. Wilkinson and Joseph Cheriyan
    Citation: Trials 2020 21:604

    The Correction to this article has been published in Trials 2020 21:641

  27. Primary objective: Evaluation of the effect of the proton pump inhibitor (PPI) pantoprazole on the absorption of hydroxychloroquine (HCQ).

    Authors: Felicitas Stoll, Antje Blank, Gerd Mikus, David Czock, Kathrin I. Foerster, Simon Hermann, Katja Häußler, Amin Muhareb, Simone Hummler, Johanna Weiss, Jürgen Burhenne and Walter E. Haefeli
    Citation: Trials 2020 21:584
  28. Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and tr...

    Authors: Helena Stockmann, Theresa Keller, Stefan Büttner, Achim Jörres, Detlef Kindgen-Milles, Julius Valentin Kunz, Josef Leebmann, Claudia Spies, Karl Träger, Sascha Treskatsch, Alexander Uhrig, Carsten Willam, Philipp Enghard and Torsten Slowinski
    Citation: Trials 2020 21:577
  29. Primary Objective:

    Authors: Carlos Tornero, Ricardo Vallejo, David Cedeño, Jorge Orduña, Ernesto Pastor, Moncef Belaouchi, Benigno Escamilla, Marisa Laredo and María del Mar Garzando
    Citation: Trials 2020 21:576
  30. In this study, we investigate the effect of hydroxychloroquine on the prevention of Novel Coronavirus Disease (COVID-19) in cancer patients being treated.

    Authors: Abolghasem Allahyari, Hossein Rahimi, Majid Khadem-Rezaiyan, Zahra Mozaheb, Mohsen Seddigh-Shamsi, Alireza Bary, Mostafa Kamandi, Sajad Ataei Azimi, Saeed Eslami HasanAbadi, Alireza Noferesti, Somayeh Sadat Shariatmaghani, Houshang Rafatpanah, Shohreh Khatami, Afshin Jabbar Imani, Hassan Mortazi and Mohammad Moeini Nodeh
    Citation: Trials 2020 21:575

    The Update to this article has been published in Trials 2021 22:349

  31. To assess whether high doses of Low Molecular Weight Heparin (LMWH) (i.e. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (i.e., Enoxaparin 4000 IU once day), in hospitalized patients w...

    Authors: Marco Marietta, Paola Vandelli, Pasquale Mighali, Roberto Vicini, Valeria Coluccio and Roberto D’Amico
    Citation: Trials 2020 21:574
  32. Tissue hypoxia is the main cause of multi-organ dysfunction in sepsis. However, effective pharmacological treatments to combat sepsis-induced tissue hypoxia are not available. Emerging experimental and clinica...

    Authors: Constantinos Pantos, Georgia Kostopanagiotou, Apostolos Armaganidis, Athanasios Trikas, Ioulia Tseti and Iordanis Mourouzis
    Citation: Trials 2020 21:573
  33. There is little information about Coronavirus Disease 2019 (COVID-19) management for critically ill patients. Most of these patients develop acute respiratory distress syndrome (ARDS) due to excessive inflamma...

    Authors: Nafiseh Abdolahi, Effat Kaheh, Roghieh Golsha, Behnaz Khodabakhshi, Alireza Norouzi, Mahmoud Khandashpoor, Sima Besharat, Samane Tavassoli, Somayeh Livani, Sadegh Ali Azimi, Mohammad Hadi Gharib, Babak Peivandi, Abdolreza Fazel, Hesamaddin Shirzad-Aski and Gholamreza Roshandel
    Citation: Trials 2020 21:549
  34. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may trigger severe pneumonia in coronavirus disease of 2019 (COVID-19) patients through release of damage-associated molecular patterns (DAMPs) and ...

    Authors: J. P. Desilles, C. Gregoire, C. Le Cossec, J. Lambert, O. Mophawe, M. R. Losser, F. Lambiotte, S. Le Tacon, M. Cantier, N. Engrand, P. Trouiller and J. Pottecher
    Citation: Trials 2020 21:548
  35. Phase I - To determine the optimal dose of each candidate (or combination of candidates) entered into the platform.

    Authors: Gareth Griffiths, Richard Fitzgerald, Thomas Jaki, Andrea Corkhill, Ellice Marwood, Helen Reynolds, Louise Stanton, Sean Ewings, Susannah Condie, Emma Wrixon, Andrea Norton, Mike Radford, Sara Yeats, Jane Robertson, Rachel Darby-Dowman, Lauren Walker…
    Citation: Trials 2020 21:544

    The Update to this article has been published in Trials 2021 22:487

  36. To assess the safety and therapeutic effects of allogeneic human dental pulp stem cells (DPSCs) in treating severe pneumonia caused by COVID-19.

    Authors: Qingsong Ye, Hua Wang, Xia Xia, Chenliang Zhou, Zhiming Liu, Zun-en Xia, Zhan Zhang, Yang Zhao, Jun Yehenala, Si Wang, Gangqiao Zhou, Ke Hu, Bin Wu, Chu-Tse Wu, Songling Wang and Yan He
    Citation: Trials 2020 21:520
  37. The aim of this randomised GCP-controlled trial is to clarify whether combination therapy with the antibiotic azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy and...

    Authors: Pradeesh Sivapalan, Charlotte Suppli Ulrik, Rasmus Dahlin Bojesen, Therese Sophie Lapperre, Josefin Viktoria Eklöf, Kjell Erik Julius Håkansson, Andrea Browatzki, Casper Tidemansen, Jon Torgny Wilcke, Julie Janner, Vibeke Gottlieb, Howraman Meteran, Celeste Porsbjerg, Birgitte Lindegaard Madsen, Mia Moberg, Lars Pedersen…
    Citation: Trials 2020 21:513

    The Update to this article has been published in Trials 2020 21:867

  38. To evaluate the safety of therapeutic plasma exchange (TPE) in adult patients with serious/life-threatening COVID-19 requiring intensive care unit (ICU) admission, and associated 28-day mortality. Serious and ...

    Authors: Fahad Faqihi, Abdulrahman Alharthy, Mohammed Alodat, Daood Asad, Waleed Aletreby, Demetrios J. Kutsogiannis, Peter G. Brindley and Dimitrios Karakitsos
    Citation: Trials 2020 21:506
  39. To determine the efficacy of Hydroxychloroquine vs. Hydroxychloroquine + Nitazoxanide in reducing the need for invasive mechanical ventilatory support for patients with COVID-19. Hydroxychloroquine is currentl...

    Authors: José Meneses Calderón, Hugo Mendieta Zerón and Srivatsan Padmanabhan
    Citation: Trials 2020 21:504
  40. The aim of this study is to evaluate the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in hospitalized adults with severe SARS-CoV-2 infection.

    Authors: Christina M. Eckhardt, Matthew J. Cummings, Kartik N. Rajagopalan, Sarah Borden, Zachary C. Bitan, Allison Wolf, Alex Kantor, Thomas Briese, Benjamin J. Meyer, Samuel D. Jacobson, Dawn Scotto, Nischay Mishra, Neena M. Philip, Brie A. Stotler, Joseph Schwartz, Beth Shaz…
    Citation: Trials 2020 21:499

    The Correction to this article has been published in Trials 2020 21:927

    The Correction to this article has been published in Trials 2020 21:536

  41. The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of p...

    Authors: Carlos Chaccour, Paula Ruiz-Castillo, Mary-Ann Richardson, Gemma Moncunill, Aina Casellas, Francisco Carmona-Torre, Miriam Giráldez, Juana Schwartz Mota, José Ramón Yuste, José Ramón Azanza, Miriam Fernández, Gabriel Reina, Carlota Dobaño, Joe Brew, Belen Sadaba, Felix Hammann…
    Citation: Trials 2020 21:498
  42. Patients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very...

    Authors: Chi Zhang, Jiawen Li, Zhao Wu, He Wang, Chengli Que, Hong Zhao and Guiqiang Wang
    Citation: Trials 2020 21:495
  43. The hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeosta...

    Authors: Cedric Bosteels, Bastiaan Maes, Karel Van Damme, Elisabeth De Leeuw, Jozefien Declercq, Anja Delporte, Bénédicte Demeyere, Stéfanie Vermeersch, Marnik Vuylsteke, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Stefaan Vandecasteele, Isabelle Peene…
    Citation: Trials 2020 21:491

    The Correction to this article has been published in Trials 2020 21:554

  44. Colchicine is a well-known drug, which has been used for years to treat a wide range of rheumatic and inflammatory disorders. It helps break the cycle of inflammation through diverse mechanisms including reduc...

    Authors: Nooshin Dalili, Alireza Kashefizadeh, Mohsen Nafar, Fatemeh Poorrezagholi, Ahmad Firouzan, Fariba Samadian, Shiva Samavat, Shadi Ziaie and Somayeh Fatemizadeh
    Citation: Trials 2020 21:489
  45. A variety of possible mechanisms can make the nucleic acid test of patients who meet the discharge conditions positive again, including reinfection, reactivation of the original virus, lack of strict discharge...

    Authors: Jiawen Li, Chi Zhang, Zhao Wu, Guiqiang Wang and Hong Zhao
    Citation: Trials 2020 21:488
  46. The hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus disease 2019 (Covid-19) is safe and will accelerate the virological clearance rate for p...

    Authors: Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø and Olav Dalgard
    Citation: Trials 2020 21:485
  47. The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination.

    Authors: Thijs ten Doesschate, Simone J. C. F. M. Moorlag, Thomas W. van der Vaart, Esther Taks, Priya Debisarun, Jaap ten Oever, Chantal P. Bleeker-Rovers, Patricia Bruijning Verhagen, Arief Lalmohamed, Rob ter Heine, Reinout van Crevel, Janneke van de Wijgert, Axel B. Janssen, Marc J. Bonten, Cornelis H. van Werkhoven and Mihai G. Netea
    Citation: Trials 2020 21:481

    The Correction to this article has been published in Trials 2020 21:555

  48. Objective: To undertake a pilot, feasibility RCT of umbilical cord blood derived cell therapy for treatment of adult patients infected with SARS-CoV-2 virus related moderate-to-severe pneumonia to prevent prog...

    Authors: Atul Malhotra, David Ernest, Benjamin A. Rogers, David Haylock, Ashalyn Watt, Guy Moeneclaey and Graham Jenkin
    Citation: Trials 2020 21:474
  49. We will investigate the effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen in COVID-19 in patients that have tested positive and are moderately to severely ill.

    Authors: Seyed Sina Naghibi Irvani, Maryam Golmohammadi, Mohamad Amin Pourhoseingholi, Shervin Shokouhi and Ilad Alavi Darazam
    Citation: Trials 2020 21:473
  50. Primary objective: to evaluate the efficacy of melatonin as a prophylactic treatment on prevention of symptomatic SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure.

    Authors: Irene García García, Miguel Rodriguez-Rubio, Amelia Rodríguez Mariblanca, Lucía Martínez de Soto, Lucía Díaz García, Jaime Monserrat Villatoro, Javier Queiruga Parada, Enrique Seco Meseguer, María J. Rosales, Juan González, José R. Arribas, Antonio J. Carcas, Pedro de la Oliva and Alberto M. Borobia
    Citation: Trials 2020 21:466